JP4617058B2 - コンセンサスインターフェロンのB型肝炎表面抗原とe抗原の抑制剤としての応用 - Google Patents
コンセンサスインターフェロンのB型肝炎表面抗原とe抗原の抑制剤としての応用 Download PDFInfo
- Publication number
- JP4617058B2 JP4617058B2 JP2002578997A JP2002578997A JP4617058B2 JP 4617058 B2 JP4617058 B2 JP 4617058B2 JP 2002578997 A JP2002578997 A JP 2002578997A JP 2002578997 A JP2002578997 A JP 2002578997A JP 4617058 B2 JP4617058 B2 JP 4617058B2
- Authority
- JP
- Japan
- Prior art keywords
- hepatitis
- antigen
- drug
- consensus interferon
- interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Description
溶剤及び調合方法:試薬の調合の際に、原料瓶ごとに1mlの生理食塩水を添加する。溶解後、あらかじめ設定されているさまざまな組み合わせの薬剤量濃度に基づき、薬剤をMEM培養液で調合する。試薬はその場で取り出しその場で使い切ることとする。
2.2.15細胞の培養:2.2.15細胞を成長させた培養瓶の中に0.25%のパンクレアチンを加え、37℃で3分間消化する。培養液を吹き付けても、1:3代生育させるのに10日かかる。
TC50=Antilog(B+───── × C)
A−B
A=log>50%薬物濃度 B=log<50%薬物濃度 C=log希釈倍数
HBeAgとHBsAgに対する抑制試験:試験ではHBeAgとHBsAgの陽性対照グループと陰性対照グループと細胞の対照グループ及び異なる濃度の薬物投与グループを設定する。1ml中の70万個の2.2.15細胞を6孔細胞培養板に1孔3ml接種し、37℃5%CO2の環境に置き、24時間培養する。これに無毒濃度以下の3倍の希釈試験薬液を添加し、5段階の希釈濃度をそれぞれ4.5×106IU/ml、1.5×106IU/ml、0.5×106IU/ml,0.17×106IU/ml、0.056×106IU/mlとし、1濃度段階に付き1孔として37℃5%CO2の環境に置いて培養する。4日ごとにもとの濃度の薬液を換え、8日目に培養液を収穫して−20℃でこれを凍結保存する。試験は3回繰り返して行い、HBeAgとHBsAgをそれぞれ測定する。HBeAgとHBsAgの測定に際しては、中国同位素公司北方免疫試剤研究所の製品を用い、ラジオアイソトープ免疫測定器により測定する。その方法については説明書を参照の上、γ−計数機器を用い各孔ごとのcpm値を測定する。
(1) 細胞対照ク゛ルーフ゜cpm−薬物投与ク゛ルーフ゜cpm
抗原抑制百分率(%)=─────────────────────×100
細胞対照cpm
(2)薬物の抑制抗原の半数の有効濃度(IC50):
50−B
IC50=Antilog(B+ ───── × C)
A−B
A=log>50%薬物濃度 B=log<50%薬物濃度 C=log希釈倍数
(3)空間構造を変えたコンセンサスインターフェロンの2.2.15細胞の培養においては、HBsAgとHBeAgの選択指数(SI)とその細胞毒性の指標細胞の病変(SI)に基づき計算する。
細胞病変毒TC50
SI=───────────────
IC50
(4)t検査法を用いて、各希釈度のHBsAgとHBeAgと対照グループ間のcpmの差を計算する。
混合ゲルをHCl・変性液、・中和液中にそれぞれ浸漬させる。(4)膜転写:プロセスに基づきDNAをHydron-Nナイロン膜に転写する。スポット交雑と同時に加熱・交雑・感光を行う。スキャナーに感光部をスキャンさせ、gel-proゲル画像定量解析ソフトを用いて相対密度を解析する。抑制率及びIC50を計算する。
本発明では、数回にわたる実験の結果(表一、表二、表三を参照)により、以下のことが明らかとなった。サンプルの最大無毒濃度のものを2.2.15細胞に添加し8日間培養した結果、コンセンサスインターフェロン最大無毒濃度9.0±0×106IU/ml、HBeAgに対する平均抑制率は46.0±5.25%(P<0.001)、IC50は4.54±1.32×106IU/ml、選択指数SIは3.96であった。また、HBsAgに対する平均抑制率は44.8±6.6%、IC50は6.49±0.42×106IU/ml、選択指数SIは2.77であった。これにより、コンセンサスインターフェロンにはB型肝炎表面抗原とe抗原に対する明らかな抑制効果が認められ、対照グループのインターフェロンとInfergenには上記のような活性は認められなかった。臨床例においても慢性活動性B型肝炎の患者に対し、コンセンサスインターフェロンの投与をすることにより、B型肝炎の表面抗原とe抗原の陽性の程度が低減され、正常レベルまで回復することが実証されている。
<実施例1> フリーズドライ注射剤の調剤
a.コンセンサスインターフェロン 300万IU
b.クエン酸 0.2mg
c.リン酸ジナトリウム 2.5mg
d.塩化ナトリウム 4.0mg
e.デキストロース 20mg
f.ポリオキシンエチレン脱水ソルビットモノオレイン酸エステル
0.1ml
g.注射用精製水 適量を加え全量1.0mlまでとする。
a.コンセンサスインターフェロン 300万IU
b.クエン酸 0.2mg
c.リン酸ジナトリウム 2.5mg
d.塩化ナトリウム 4.0mg
e.デキストロース 20mg
f.ポリオキシンエチレン脱水ソルビットモノオレイン酸エステル
0.1ml
g.注射用精製水 適量を加え全量1.0mlまでとする。
Claims (5)
- 下記の遺伝子配列を用いて製造された下記のアミノ酸配列よりなるコンセンサスインターフェロンを含有することを特徴とする組成物。
- B型肝炎ウイルス(HBV)を阻害することを特徴とする請求項1記載の組成物。
- B型肝炎ウイルスDNAの複製、及びHBsAg並びにHBeAgの分泌を阻害することを特徴とする請求項1記載の組成物。
- 組成物は、経口投与、静脈注射、筋肉注射、皮下注射、経鼻投与または粘膜塗布により投与可能な剤形であることを特徴とする請求項2〜4のいずれかに記載の組成物。
- 請求項1記載の組み換えインターフェロンを9〜15μg含有することを特徴とする請求項2〜5のいずれかに記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB011043679A CN1245215C (zh) | 2001-02-28 | 2001-02-28 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
CN01104367.9 | 2001-02-28 | ||
PCT/CN2002/000128 WO2002080958A1 (fr) | 2001-02-28 | 2002-02-28 | Interferon supercompose de recombinaison utilise comme inhibiteur de l'antigene de surface et de l'antigene e de l'hepatite b |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005508848A JP2005508848A (ja) | 2005-04-07 |
JP2005508848A6 JP2005508848A6 (ja) | 2005-08-04 |
JP4617058B2 true JP4617058B2 (ja) | 2011-01-19 |
Family
ID=4653854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002578997A Expired - Lifetime JP4617058B2 (ja) | 2001-02-28 | 2002-02-28 | コンセンサスインターフェロンのB型肝炎表面抗原とe抗原の抑制剤としての応用 |
Country Status (10)
Country | Link |
---|---|
US (3) | US7364724B2 (ja) |
EP (1) | EP1371373B1 (ja) |
JP (1) | JP4617058B2 (ja) |
CN (1) | CN1245215C (ja) |
AT (1) | ATE446104T1 (ja) |
AU (1) | AU2003248419B2 (ja) |
CA (1) | CA2439503A1 (ja) |
DE (1) | DE60234085D1 (ja) |
HK (1) | HK1061201A1 (ja) |
WO (1) | WO2002080958A1 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050079579A1 (en) * | 2001-02-28 | 2005-04-14 | Guangwen Wei | Uses of spatial configuration to modulate protein function |
US8551469B2 (en) | 2001-02-28 | 2013-10-08 | Superlab Far East Limited | Treatment of tumors and viral diseases with recombinant interferon alpha |
CN1245215C (zh) | 2001-02-28 | 2006-03-15 | 四川省生物工程研究中心 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
US20060035327A1 (en) * | 2001-02-28 | 2006-02-16 | Guangwen Wei | Recombinant super-compound interferon and uses thereof |
US7335496B2 (en) * | 2003-06-05 | 2008-02-26 | Ajinomoto Co., Inc. | Method for producing target substance |
AU2011202683B2 (en) * | 2003-08-28 | 2012-08-09 | Superlab Far East Limited | Uses of interferons with altered spatial structure |
US7585647B2 (en) | 2003-08-28 | 2009-09-08 | Guangwen Wei | Nucleic acid encoding recombinant interferon |
EP1663110B1 (en) * | 2003-08-28 | 2013-12-18 | Superlab Far East Limited | Uses of interferons with altered spatial structure |
SI1663110T1 (sl) * | 2003-08-28 | 2014-04-30 | Superlab Far East Limited | Uporaba interferonov s spremenjeno prostorsko strukturo |
CN1740197B (zh) * | 2004-08-26 | 2010-05-12 | 辉阳科技美国公司 | 具有全新空间构象且功效增强的重组干扰素、其制备方法及应用 |
WO2006134497A2 (en) * | 2005-03-09 | 2006-12-21 | Guangwen Wei | Uses of recombinant super-compound interferons |
CN101525381B (zh) * | 2008-03-04 | 2012-04-18 | 北京百川飞虹生物科技有限公司 | 一种重组复合干扰素及其表达载体的构建和表达 |
CN102101886A (zh) * | 2009-12-18 | 2011-06-22 | 四川辉阳生命工程股份有限公司 | 构象改变的重组干扰素晶体、其三维结构及应用 |
WO2013055811A1 (en) * | 2011-10-12 | 2013-04-18 | Hitachi Chemical Co., Ltd. | Ex vivo methods of predicting responsiveness of a subject to interferon therapy |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
JP5677645B2 (ja) | 2011-10-21 | 2015-02-25 | アッヴィ・インコーポレイテッド | 少なくとも2種の直接作用型抗ウイルス剤、およびリバビリンを含むがインターフェロンを含まない、hcvを治療するための方法 |
CN104436197A (zh) | 2011-10-21 | 2015-03-25 | 艾伯维公司 | 至少两种直接作用抗病毒剂的组合产品 |
TWI718086B (zh) | 2013-01-07 | 2021-02-11 | 英屬維爾京群島商遠東超級實驗室有限公司 | 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物 |
US10677782B2 (en) | 2013-11-13 | 2020-06-09 | Superlab Far East Limited | Methods of determining interferon having direct inhibitory effects on tumors and uses thereof |
CN107847564B (zh) | 2015-05-12 | 2021-11-09 | 远东超级实验室有限公司 | 鉴定对肿瘤具有直接抑制作用的干扰素的方法及其用途 |
EP3448392A4 (en) | 2016-04-28 | 2020-01-15 | Emory University | ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
DK159164C (da) | 1981-12-07 | 1991-02-11 | Hoffmann La Roche | Fremgangsmaade til fremstilling af humant leukocytinterferon i krystallinsk form |
US4672108A (en) * | 1981-12-07 | 1987-06-09 | Hoffmann-La Roche Inc. | Crystalline human leukocyte interferon |
US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4462940A (en) * | 1982-09-23 | 1984-07-31 | Cetus Corporation | Process for the recovery of human β-interferon-like polypeptides |
US4681930A (en) * | 1983-09-20 | 1987-07-21 | Hoffmann-La Roche Inc. | Immune interferon and a method for its extraction and purification |
US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
US5441734A (en) | 1993-02-25 | 1995-08-15 | Schering Corporation | Metal-interferon-alpha crystals |
DE4329756A1 (de) | 1993-09-03 | 1995-03-09 | Boehringer Ingelheim Int | Verfahren zur Herstellung und Reinigung von alpha-Interferon |
EP0626448A3 (de) | 1993-05-26 | 1998-01-14 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Verfahren zur Herstellung und Reinigung von alpha-Interferon |
US5766582A (en) | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
TW426523B (en) | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
CA2232230C (en) * | 1995-10-13 | 2005-06-28 | Ralph H. Lambalot | Phosphopantetheinyl transferases and uses thereof |
US5972331A (en) * | 1995-12-22 | 1999-10-26 | Schering Corporation | Crystalline interferon alpha for pulmonary delivery and method for producing the same |
US5874304A (en) * | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
US5980884A (en) | 1996-02-05 | 1999-11-09 | Amgen, Inc. | Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon |
US6532437B1 (en) * | 1996-10-23 | 2003-03-11 | Cornell Research Foundation, Inc. | Crystalline frap complex |
CN1186120A (zh) | 1996-12-24 | 1998-07-01 | 深圳科兴生物制品有限公司 | 在大肠杆菌中表达作为分泌的重组人干扰素α1b蛋白 |
WO1999029862A1 (en) * | 1997-12-05 | 1999-06-17 | Human Genome Sciences, Inc. | Synferon, a synthetic type i interferon |
US6087478A (en) * | 1998-01-23 | 2000-07-11 | The Rockefeller University | Crystal of the N-terminal domain of a STAT protein and methods of use thereof |
WO1999040117A1 (en) | 1998-02-06 | 1999-08-12 | Ilexus Pty. Limited | THREE-DIMENSIONAL STRUCTURES AND MODELS OF Fc RECEPTORS AND USES THEREOF |
CN1062565C (zh) | 1998-06-29 | 2001-02-28 | 深圳九先生物工程有限公司 | 重组人α型复合干扰素及其制备方法和用途 |
KR100399156B1 (ko) | 1999-11-19 | 2003-09-26 | 주식회사 엘지생명과학 | α-인터페론의 용액제형 |
CN1175901C (zh) | 1999-12-06 | 2004-11-17 | 天津华立达生物工程有限公司 | 一种稳定的干扰素水溶液 |
US20020043262A1 (en) * | 2000-08-22 | 2002-04-18 | Alan Langford | Spray device |
US7544354B2 (en) * | 2000-10-27 | 2009-06-09 | Novartis Vaccines And Diagnostics | Methods of protein purification and recovery |
CA2427850A1 (en) | 2000-11-03 | 2002-05-10 | Sidney Pestka | Interferons, uses and compositions related thereto |
CN1245215C (zh) | 2001-02-28 | 2006-03-15 | 四川省生物工程研究中心 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
US6546074B1 (en) * | 2001-03-27 | 2003-04-08 | Astex Technology Limited | Protein crystal structure and method for identifying protein modulators |
CN1375502A (zh) | 2001-10-25 | 2002-10-23 | 南京药科大学 | 聚乙二醇修饰重组人干扰素 |
US6807478B2 (en) * | 2001-12-27 | 2004-10-19 | Koninklijke Philips Electronics N.V. | In-building navigation system |
CN1176946C (zh) | 2002-05-16 | 2004-11-24 | 中国人民解放军第二军医大学 | 一种新型α干扰素 |
CN1202861C (zh) | 2003-07-18 | 2005-05-25 | 中国科学院微生物研究所 | 复合干扰素在治疗sars疾病中的用途 |
EP1663110B1 (en) | 2003-08-28 | 2013-12-18 | Superlab Far East Limited | Uses of interferons with altered spatial structure |
WO2005067963A1 (en) | 2003-12-23 | 2005-07-28 | Intermune, Inc. | Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens |
WO2006134497A2 (en) | 2005-03-09 | 2006-12-21 | Guangwen Wei | Uses of recombinant super-compound interferons |
-
2001
- 2001-02-28 CN CNB011043679A patent/CN1245215C/zh not_active Expired - Lifetime
-
2002
- 2002-02-28 EP EP02702211A patent/EP1371373B1/en not_active Expired - Lifetime
- 2002-02-28 DE DE60234085T patent/DE60234085D1/de not_active Expired - Lifetime
- 2002-02-28 WO PCT/CN2002/000128 patent/WO2002080958A1/zh active Application Filing
- 2002-02-28 JP JP2002578997A patent/JP4617058B2/ja not_active Expired - Lifetime
- 2002-02-28 AT AT02702211T patent/ATE446104T1/de not_active IP Right Cessation
- 2002-02-28 CA CA002439503A patent/CA2439503A1/en not_active Abandoned
-
2003
- 2003-08-28 US US10/650,365 patent/US7364724B2/en not_active Expired - Lifetime
- 2003-09-26 AU AU2003248419A patent/AU2003248419B2/en not_active Expired
-
2004
- 2004-06-15 HK HK04104296.9A patent/HK1061201A1/xx not_active IP Right Cessation
-
2008
- 2008-04-18 US US12/105,455 patent/US8114395B2/en not_active Expired - Fee Related
-
2011
- 2011-02-01 US US13/019,044 patent/US8425896B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1245215C (zh) | 2006-03-15 |
CA2439503A1 (en) | 2002-10-17 |
EP1371373B1 (en) | 2009-10-21 |
WO2002080958A1 (fr) | 2002-10-17 |
US8114395B2 (en) | 2012-02-14 |
US8425896B2 (en) | 2013-04-23 |
EP1371373A4 (en) | 2005-05-04 |
US20110189128A1 (en) | 2011-08-04 |
AU2003248419A1 (en) | 2003-11-06 |
HK1061201A1 (en) | 2004-09-10 |
EP1371373A1 (en) | 2003-12-17 |
CN1311035A (zh) | 2001-09-05 |
ATE446104T1 (de) | 2009-11-15 |
US20040202641A1 (en) | 2004-10-14 |
US7364724B2 (en) | 2008-04-29 |
JP2005508848A (ja) | 2005-04-07 |
DE60234085D1 (de) | 2009-12-03 |
AU2003248419B2 (en) | 2007-01-04 |
US20080305080A1 (en) | 2008-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4617058B2 (ja) | コンセンサスインターフェロンのB型肝炎表面抗原とe抗原の抑制剤としての応用 | |
JP2005508848A6 (ja) | コンセンサスインターフェロンのB型肝炎表面抗原とe抗原の抑制剤としての応用 | |
AU674306B2 (en) | Improved alpha interferon composition and method for its production from human peripheral blood leukocytes | |
JPH03246232A (ja) | ヒト免疫インターフェロン | |
JP5709800B2 (ja) | 変えられた空間構造を備えるインターフェロン及びその応用 | |
US20150174206A1 (en) | Uses of interferons with altered spatial structure | |
US20100061961A1 (en) | Recombinant super-compound interferon | |
JPH0550273B2 (ja) | ||
US20060035327A1 (en) | Recombinant super-compound interferon and uses thereof | |
EP1105467B9 (en) | USE OF MODIFIED LYSOZYME c TO PREPARE MEDICINAL COMPOSITIONS FOR THE TREATMENT OF SOME SERIOUS DISEASES | |
CN101244263A (zh) | 包含混合干扰素-α亚型的混合物 | |
US20180258151A1 (en) | Recombinant super-compound interferon and uses thereof | |
CN100535006C (zh) | Glp-1类似物 | |
DK171419B1 (da) | Mikrobielt fremstillet humant Interleukin-1, fremgangsmåder til fremstilling deraf samt farmaceutiske preparater indeholdende dette, og dets anvendelse i behandling og profylakse | |
RU2809360C1 (ru) | РЕКОМБИНАНТНАЯ ПЛАЗМИДА pET32a-IFG144, ОБЕСПЕЧИВАЮЩАЯ СИНТЕЗ ИНТЕРФЕРОНА ГАММА, ШТАММ БАКТЕРИЙ ESCHERICHIA COLI JM109/pET32a-IFG144 - ПРОДУЦЕНТ БЕЛКА ИНТЕРФЕРОН ГАММА, СПОСОБ ПОЛУЧЕНИЯ ИНТЕРФЕРОНА ГАММА И ЛЕКАРСТВЕННОЕ СРЕДСТВО | |
RU2809358C1 (ru) | РЕКОМБИНАНТНАЯ ПЛАЗМИДА pET32a-IFG144, ОБЕСПЕЧИВАЮЩАЯ СИНТЕЗ ИНТЕРФЕРОНА ГАММА, ШТАММ БАКТЕРИЙ ESCHERICHIA COLI JM109/pET32a-IFG144 - ПРОДУЦЕНТ БЕЛКА ИНТЕРФЕРОН ГАММА, СПОСОБ ПОЛУЧЕНИЯ ИНТЕРФЕРОНА ГАММА И ЛЕКАРСТВЕННОЕ СРЕДСТВО | |
KR950008569B1 (ko) | 신규 림포카인(lymphokine) 및 그 제조방법과 사용방법 | |
KR100285586B1 (ko) | 5-하드록시메틸-2-푸르푸랄을 함유하는 비형 간염 치료제 | |
CN116685598A (zh) | 干扰素taufc-融合蛋白和治疗方法冠状病毒感染 | |
EP0318302A1 (en) | Proteinaceous compositions | |
JPS61205214A (ja) | 腫瘍細胞障害性物質 | |
JPH05271280A (ja) | 新規ポリペプチド、その製造方法及び該ポリペプチドを 有効成分とする医薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050225 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080617 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080912 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081030 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091215 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100312 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100325 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100406 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100413 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100614 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100927 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101025 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4617058 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131029 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |